Magenta Therapeutics reports Q4 2021 net loss $19.3M; first patient dosed in MGTA-117 trial

Dianthus Therapeutics, Inc. /DE/

Cash, cash equivalents and marketable securities at Dec 31, 2021: $176.9M, expected to fund operations into Q4 2023.
First patient dosed and completed initial safety assessment in Phase 1/2 trial of MGTA-117 targeted conditioning; data expected in 2022.
IND-enabling studies initiated for CD45-ADC; dose-ranging toxicology results anticipated in H2 2022.
MGTA-145 stem cell mobilization program advancing in sickle cell disease; data expected in H2 2022.
Net loss of $19.3M for Q4 2021 vs. $18.2M in Q4 2020; R&D expenses increased to $13.1M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.